Association between rs12979860, rs17047200 and rs4618569 Variant Polymorphisms with the Course and Outcome of SARS-CoV-2 Patients.

BACKGROUND

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection provides a critical host-immunological challenge.

AIM

We explore the effect of host-genetic variation in interferon-lambda-3 rs12979860, Tolloid Like-1 () rs17047200 and Discoidin domain receptor 1() rs4618569 on host response to respiratory viral infections and disease severity that may probe the mechanistic approach of allelic variation in virus-induced inflammatory responses.

METHODS

141 COVID-19 positive patients and 100 healthy controls were tested for interferon-lambda-3 rs12979860, rs17047200 and DDR1 rs4618569 polymorphism by TaqMan probe-based genotyping. Different genotypes were assessed regarding the COVID-19 severity and prognosis.

RESULTS

There were statistically significant differences between the studied cases and control group with regard to the presence of comorbidities, total leucocytic count, lymphocytic count, CRP, serum LDH, ferritin and D-dimer ( < 0.01). The CC genotype of rs12979860 cytokine, the AA genotype of rs17047200 and the AA genotype of the rs4618569 variant of showed a higher incidence of COVID-19 compared to the others. There were significant differences between the rs4618569 variant of and the outcome of the disease, with the highest mortality in AG genotype 29 (60.4%) in comparison to 16 (33.3%) and 3 (6.2%) in the AA and GG genotypes, respectively ( = 0.007*), suggesting that the A allele is associated with a poor outcome in the disease.

CONCLUSION

Among people who carry C and A alleles of SNPs rs12979860 and rs17047200, respectively, the AG genotype of the DDR1 rs4618569 variant is correlated with a COVID-19 poor outcome. In those patients, the use of anti-, and therapy may be promising for personalized translational clinical practice.